11.4 Non-Malignant Hematologic Disorders: ITP, Aplastic Anemia, Sickle Cell Disease & TTP
Key Takeaways
BPS includes non-malignant hematology in the BCOP target population; blueprint task 2A2 explicitly tests immune thrombocytopenia, aplastic anemia, and sickle cell disease pharmacotherapy.
ITP first-line therapy is a short corticosteroid course (dexamethasone 40 mg x 4 days) with IVIG for urgent counts; second-line therapy centers on TPO receptor agonists — eltrombopag must be separated from food, dairy, and cations by 4 hours.
Severe aplastic anemia is treated with matched-sibling allogeneic HSCT in young patients or with horse ATG + cyclosporine + eltrombopag triple immunosuppression (RACE-trial standard) when transplant-ineligible.
Hydroxyurea titrated to the maximum tolerated dose (MCV rise marks adherence) is first-line disease-modifying therapy in sickle cell disease; voxelotor was withdrawn worldwide in 2024, and gene therapies (exagamglogene autotemcel, lovotibeglogene autotemcel) are curative options for patients aged 12 and older.
TTP (ADAMTS13 activity <10%) requires emergent plasma exchange plus caplacizumab, corticosteroids, and rituximab; platelet transfusion is relatively contraindicated, and drug-induced TMA (gemcitabine, carfilzomib) is managed by drug withdrawal rather than PLEX.
1. Why Benign Hematology Is in the BCOP Scope
The BPS BCOP target population explicitly includes pharmacists who manage clinical situations associated with non-malignant hematology, and blueprint task 2A2 (Treatment of Non-Malignant Hematologic Disorders) names aplastic anemia, immune thrombocytopenia (ITP), and sickle cell disease as exemplars. In practice, oncology pharmacists own these disorders because they share drugs (rituximab, corticosteroids, eltrombopag), supportive-care infrastructure (transfusion services, chelation, infection prophylaxis), and diagnostic reasoning (is this cytopenia marrow invasion, chemotherapy effect, or a primary hematologic disease?) with malignant hematology.
2. Immune Thrombocytopenia (ITP)
Definition: isolated thrombocytopenia (platelets <100 x 10^9/L) without other cytopenias or an alternative cause; a diagnosis of exclusion. Always classify as primary or secondary (SLE, CLL/lymphoma, H. pylori, HCV, HIV, or drug-induced — vancomycin, heparin, and even some antineoplastics), because treating the driver treats the platelets.
| Line | Agents | Board Pearls |
|---|---|---|
| First-line | Dexamethasone 40 mg PO x 4 days (preferred over prolonged prednisone tapers) or prednisone 1 mg/kg/day | Treat when platelets <20-30 x 10^9/L or bleeding; observation is acceptable above that in asymptomatic adults |
| Urgent (wet bleeding / platelets <10k) | IVIG 1 g/kg x 1-2 days; anti-Rh(D) immune globulin (Rh-positive, non-splenectomized only — boxed warning for intravascular hemolysis); high-dose IV corticosteroids; platelet transfusion reserved for life-threatening hemorrhage | IVIG raises platelets within 24-48 h but the effect wanes in 2-4 weeks |
| Second-line | TPO receptor agonists: eltrombopag 50 mg PO daily (empty stomach; separate from dairy, antacids, and divalent cations by 4 hours; hepatotoxicity monitoring), romiplostim 1-10 mcg/kg SC weekly (titrate to platelets), avatrombopag 20-40 mg PO daily with food (no chelation issue) | Eltrombopag food/cation chelation is a favorite exam trap |
| Second-line (immune) | Rituximab 375 mg/m2 weekly x 4 (durable responses in ~20-30%); fostamatinib 100 mg PO BID (SYK inhibitor; hypertension, transaminitis) | HBV screening before rituximab |
| Definitive | Splenectomy (highest durable remission rate; defer >=1-2 years from diagnosis) | Pre-splenectomy vaccines: pneumococcal, meningococcal (ACWY + B), and Hib — pharmacist-owned catch-up |
3. Aplastic Anemia (AA)
Recognition: pancytopenia with a hypocellular marrow (<25-30% cellularity); exclude hypocellular MDS, paroxysmal nocturnal hemoglobinuria (clone testing), and drug/radiation exposure. Severity (Camitta): severe AA = marrow cellularity <25-30% plus at least two of ANC <500/mcL, platelets <20 x 10^9/L, or absolute reticulocyte count <20-40 x 10^9/L.
- Young patients (<40-50 years) with a matched sibling donor: upfront allogeneic HSCT is curative and preferred.
- Transplant-ineligible patients: immunosuppressive therapy (IST) with horse antithymocyte globulin (hATG) + cyclosporine + eltrombopag — adding eltrombopag upfront to hATG/cyclosporine (the RACE-trial regimen) improved complete and overall hematologic response rates and is the current standard triple regimen. Rabbit ATG is inferior for AA.
- Supportive care: irradiated, leukoreduced blood products; minimize transfusions (especially from family members) in potential HSCT candidates to prevent alloimmunization; iron chelation (deferasirox) for transfusion iron overload; infection prophylaxis when severely neutropenic; single-agent G-CSF is not disease-modifying.
A 41-year-old patient with persistent primary immune thrombocytopenia (platelets 22 x 10^9/L, no active bleeding) relapses after an initial response to dexamethasone 40 mg daily x 4 days. The team elects to start eltrombopag. Which counseling point is essential for the pharmacist to provide?
Take eltrombopag with a calcium-rich breakfast and an antacid to minimize gastrointestinal upset
Take eltrombopag on an empty stomach and separate it from dairy products, antacids, and mineral supplements by at least 4 hours because polyvalent cations chelate the drug and abolish absorption; liver enzymes require periodic monitoring
Administer eltrombopag by subcutaneous injection once weekly, titrating the dose to the platelet count
No dietary precautions exist; the drug is unaffected by food or cations
4. Sickle Cell Disease (SCD)
Pathophysiology: point mutation substituting valine for glutamate at beta-globin position 6 -> deoxygenated HbS polymerizes -> sickled erythrocytes drive vaso-occlusive crises (VOC), acute chest syndrome, stroke, splenic infarction (functional asplenia), priapism, and chronic kidney disease.
| Intervention | Detail | Board Pearl |
|---|---|---|
| Hydroxyurea (first-line disease-modifying) | Start ~15 mg/kg/day; titrate every 8 weeks to a maximum tolerated dose (~35 mg/kg/day); induces fetal hemoglobin (HbF), reduces VOC frequency, acute chest events, and mortality | Rising MCV is the adherence/response marker; monitor CBC every 4-8 weeks during titration for myelosuppression |
| L-glutamine (Endari) | Oral powder twice daily; modest VOC reduction | Second-line add-on |
| Voxelotor (Oxbryta) | HbS polymerization inhibitor | Voluntarily withdrawn worldwide by the manufacturer in September 2024 after phase 3 data showed more vaso-occlusive crises and deaths in the voxelotor arm — do not initiate |
| Chronic transfusions | Simple or exchange transfusion for stroke prevention (children) and recurrent severe complications | Iron overload after ~10-20 transfusions -> chelation (deferasirox, deferoxamine); alloimmunization risk — extended RBC antigen matching |
| Curative options | Matched-sibling allogeneic HSCT; FDA-approved gene therapies for ages >=12: exagamglogene autotemcel (Casgevy, CRISPR BCL11A editing) and lovotibeglogene autotemcel (Lyfgenia, lentiviral — boxed warning for hematologic malignancy) | Oncology pharmacists manage myeloablative busulfan conditioning for these cellular therapies |
| Infection prevention | Penicillin prophylaxis in young children (PCN VK 125-250 mg BID); pneumococcal, meningococcal, and Hib vaccination for functional asplenia | Same asplenia bundle as post-splenectomy |
| VOC management | Rapid multimodal analgesia (NSAID + scheduled opioid), incentive spirometry, cautious hydration (avoid overload), treat triggers | Acute chest syndrome: broad-spectrum antibiotics + exchange transfusion |
5. Thrombotic Microangiopathies: TTP and Drug-Induced TMA
- Thrombotic thrombocytopenic purpura (TTP): microangiopathic hemolytic anemia (schistocytes, high LDH, low haptoglobin) + thrombocytopenia; ADAMTS13 activity <10% confirms it. The full pentad (fever, neuro changes, renal dysfunction) is rare — do not wait for it. Treatment is an emergency: therapeutic plasma exchange (PLEX) within 4-6 hours, plus corticosteroids, caplacizumab (anti-vWF nanobody; increases bleeding, hold around invasive procedures), and rituximab. Platelet transfusion is relatively contraindicated (thrombosis propagation) unless bleeding is life-threatening.
- Drug-induced thrombotic microangiopathy: gemcitabine (cumulative-dose related), carfilzomib, quinine, calcineurin inhibitors, and VEGF-pathway inhibitors cause a PLEX-unresponsive TMA — management is immediate drug withdrawal and supportive care; eculizumab is reserved for complement-mediated disease (atypical HUS).
- Rapid differentiation board trap: TTP/HUS = normal PT/aPTT; DIC = prolonged PT/aPTT with low fibrinogen; HIT = heparin exposure, 4Ts score, stop all heparin and start argatroban or fondaparinux (never warfarin alone during acute HIT).
6. Transfusion & Supportive-Care Principles the BCOP Owns
- Product selection: irradiated cellular products for HSCT recipients, Hodgkin lymphoma, and purine-analog (fludarabine) exposure to prevent transfusion-associated GVHD; leukoreduction reduces alloimmunization and CMV transmission.
- Thresholds: prophylactic platelets at <=10 x 10^9/L (<=50k for invasive procedures); restrictive red-cell thresholds (~7-8 g/dL) in stable patients.
- Transfusion reactions: acute hemolytic (ABO — stop transfusion immediately), TRALI (new hypoxemia/infiltrates within 6 h — supportive), TACO (volume overload — diurese), allergic/anaphylactic (IgA deficiency — washed products).
- ESA boundary: erythropoiesis-stimulating agents are reserved for chemotherapy-induced anemia in non-curative settings (Hb <10 g/dL); they are not indicated for benign cytopenias and carry thromboembolic and tumor-progression warnings.
A 29-year-old woman is diagnosed with severe aplastic anemia (marrow cellularity 10%, ANC 280/mcL, platelets 12 x 10^9/L). She has no matched sibling donor and no HLA-matched unrelated donor readily available. Which initial treatment strategy is most appropriate?
Single-agent filgrastim (G-CSF) titrated to normalize the neutrophil count
Azacitidine 75 mg/m2 for 7 days repeated every 28 days
Horse antithymocyte globulin (hATG) plus cyclosporine plus eltrombopag triple immunosuppressive therapy, with irradiated leukoreduced transfusion support
Danazol monotherapy with monthly iron panels
A 24-year-old patient with sickle cell disease and three vaso-occlusive crises in the past year is being counseled on disease-modifying therapy. Which statement reflects current evidence and regulatory status?
Voxelotor is the preferred first-line oral agent and should be started immediately at 1,500 mg daily
Crizanlizumab infusions cure sickle cell disease when given for 12 consecutive months
Penicillin prophylaxis should be reserved until after the first documented pneumococcal bacteremia
Hydroxyurea titrated to the maximum tolerated dose increases fetal hemoglobin and reduces crisis frequency, and a rising MCV is a practical marker of adherence and response; voxelotor was withdrawn from the global market in 2024
A 58-year-old patient presents with confusion, platelets 9 x 10^9/L, schistocytes on smear, LDH 1,850 U/L, undetectable haptoglobin, creatinine 2.1 mg/dL, and normal PT/aPTT. ADAMTS13 activity returns at 4%. Which management sequence is most appropriate?
Emergent therapeutic plasma exchange plus corticosteroids and caplacizumab, with rituximab consideration; withhold platelet transfusion unless bleeding is life-threatening
Immediate platelet transfusion to 50 x 10^9/L followed by high-dose aspirin and clopidogrel dual antiplatelet therapy
IVIG 1 g/kg daily for 2 days with therapeutic enoxaparin for thromboprotection
Eculizumab 900 mg IV weekly monotherapy without plasma exchange
Sections you finish are checked off in the contents.